Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Merrimack Pharmaceuticals Inc (MACK)

Merrimack Pharmaceuticals Inc (MACK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 159,847
  • Shares Outstanding, K 13,410
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,460 K
  • 60-Month Beta 1.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.94
Trade MACK with:

Options Overview Details

View History
  • Implied Volatility 27.95% ( -2.00%)
  • Historical Volatility 27.77%
  • IV Percentile 1%
  • IV Rank 2.28%
  • IV High 899.06% on 11/07/22
  • IV Low 7.62% on 06/09/22
  • Put/Call Vol Ratio 0.22
  • Today's Volume 33
  • Volume Avg (30-Day) 614
  • Put/Call OI Ratio 0.94
  • Today's Open Interest 22,284
  • Open Int (30-Day) 24,411

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.09 +7.39%
on 01/25/23
12.68 -6.07%
on 01/20/23
-0.09 (-0.75%)
since 01/06/23
3-Month
10.10 +17.92%
on 12/22/22
13.66 -12.81%
on 11/09/22
+7.91 (+197.75%)
since 11/08/22
52-Week
3.00 +297.00%
on 10/10/22
13.66 -12.81%
on 11/09/22
+6.18 (+107.85%)
since 02/08/22

Most Recent Stories

More News
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “ Company ” or “ Merrimack ”), announced today that its Board of Directors (the “ Board ”) has extended the Section 382 net operating loss...

MACK : 11.91 (-0.08%)
The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and Seagen

Highlights Merrimack Pharmaceuticals, Moderna and Seagen are included in this Analyst Blog.

MRNA : 164.34 (-3.93%)
SGEN : 136.89 (-0.40%)
MACK : 11.91 (-0.08%)
Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More

Pipeline updates from MACK and MRNA are the key highlights from the biotech sector during the past week.

MRNA : 164.34 (-3.93%)
SGEN : 136.89 (-0.40%)
MACK : 11.91 (-0.08%)
BCLI : 2.20 (-10.20%)
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech giant Ipsen S.A. for approximately $1 billion, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)...

ONCY : 1.6600 (-5.14%)
ONC.TO : 2.22 (-5.53%)
SGEN : 136.89 (-0.40%)
MRTX : 50.52 (-5.94%)
AMGN : 240.20 (-1.56%)
MACK : 11.91 (-0.08%)
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –November 15, 2022 – USA News Group  –  Roughly five years after selling its flagship cancer asset Onivyde from to French...

ONCY : 1.6600 (-5.14%)
ONC.TO : 2.22 (-5.53%)
SGEN : 136.89 (-0.40%)
MRTX : 50.52 (-5.94%)
AMGN : 240.20 (-1.56%)
MACK : 11.91 (-0.08%)
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MACK),(NASDAQ:NRBO),(NYSE:MRK),(NASDAQ:RNAZ), EQNX::TICKER_END

ONCY : 1.6600 (-5.14%)
ONC.TO : 2.22 (-5.53%)
MACK : 11.91 (-0.08%)
NRBO : 0.7850 (-2.48%)
MRK : 106.64 (+0.91%)
RNAZ : 0.5300 (-6.26%)
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - The pancreatic cancer treatment market is fiercely competitive. To maintain the escalating market...

ONC.TO : 2.22 (-5.53%)
ONCY : 1.6600 (-5.14%)
MACK : 11.91 (-0.08%)
NRBO : 0.7850 (-2.48%)
MRK : 106.64 (+0.91%)
RNAZ : 0.5300 (-6.26%)
Merrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] announced that Ipsen, SA (“Ipsen”) issued a press release today reporting its primary analysis of the results...

MACK : 11.91 (-0.08%)
Merrimack Reports Third Quarter 2022 Financial Results

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its third quarter 2022 financial results for the period ended September 30, 2022.

MACK : 11.91 (-0.08%)
Merrimack Reports Second Quarter 2022 Financial Results

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its second quarter 2022 financial results for the period ended June 30, 2022.

MACK : 11.91 (-0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merrimack Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery, development and preparation to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with a special focus on cancer. Merrimack Pharmaceuticals, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 12.27
2nd Resistance Point 12.16
1st Resistance Point 12.03
Last Price 11.91
1st Support Level 11.80
2nd Support Level 11.69
3rd Support Level 11.56

See More

52-Week High 13.66
Last Price 11.91
Fibonacci 61.8% 9.59
Fibonacci 50% 8.33
Fibonacci 38.2% 7.07
52-Week Low 3.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar